摘要
目的检测TRAIL受体DR5、DcR1在宫颈癌中的表达及意义,探讨其在诱导肿瘤细胞凋亡中的作用。方法采用免疫组化ElivisionTMplus法检测DR5、DcR1在正常宫颈组织、宫颈上皮内瘤样病变(CIN)和宫颈癌组织中的表达情况,并分析其与临床病理的关系。结果 DR5在正常宫颈组织中阳性表达率为10.00%,显著低于CIN组(80.00%)和宫颈癌组(92.86%),差异具有统计学意义(P<0.01);DcR1在正常宫颈组织、CIN组织和宫颈癌组织中阳性表达率分别为90.00%、90.00%和97.62%,各组间差异无统计学意义(P>0.05)。DR5、DcR1的阳性表达率与宫颈癌的临床分期、病理分型以及淋巴结转移无明显相关性。结论 DR5和DcR1在宫颈癌中均为高表达,可能成为新的治疗靶点。
Objective To investigate the expression of tumor necrosis factors related apoptosis induced ligand（ TRAIL） receptors, DR5 and DcR1 ,in cervical cancer and their roles in the apoptosis of tumor cells. Methods Immunohistochemical ElivisionTM plus tech- nique was adopted to detect the positive expression of DR5 and DcR1 in cervical cancer, CIN and normal cervical epithelium. Their cor- relations with clinical pathology were analyzed. Results The positive rates of DR5 were significantly higher in CIN （ 80.00% ） and cervical cancer（92.86% ）than that in normal cervical epithelium（ 10.00% ）. There was no significant difference in the positive rate of DcR1 among cervical cancer（97.62% ）,CIN （90.00%）and normal cervical epithelium（90.00% ）. The positive rates of DR5 and DcR1 were not related with clinical stage,histological type and lymph node metastasis of cervical cancer. Conclusion DIL5 and DcR1 are highly expressed in cervical cancer and could be new targets for the clinical treatment of cervical cancer.
出处
《山西医科大学学报》
CAS
2012年第9期690-692,F0003,共4页
Journal of Shanxi Medical University
